Skip to main content
. 2014 Apr 11;35(31):2083–2093. doi: 10.1093/eurheartj/ehu160

Table 1.

Baseline characteristics and invasive procedures by randomized treatment in the overall NSTE-ACS population, and by initial treatment strategy (within the first 10 days after randomization)

  Overall NSTE-ACS
NSTE-ACS with revascularization
NSTE-ACS without revascularization
Ticagrelor (N = 5581) Clopidogrel (N = 5499) Ticagrelor (N = 2873) Clopidogrel (N = 2841) Ticagrelor (N = 2708) Clopidogrel (N = 2658)
Demographics
 Age, median (25th–75th percentile), years 64 (56–72) 64 (56–72) 63 (55–71) 63 (55–71) 65 (57–73) 65 (57–73)
 Age ≥ 75 years, n (%) 955 (17.1) 1024 (18.6) 420 (14.6) 460 (16.2) 535 (19.8) 564 (21.2)
 Female gender, n (%) 1746 (31.3) 1746 (31.8) 706 (24.6) 716 (25.2) 1040 (38.4) 1030 (38.8)
 Body weight <60 kg, n (%) 398 (7.2) 389 (7.1) 165 (5.8) 172 (6.1) 233 (8.6) 217 (8.2)
 Body mass index, median (25th–75th percentile), kg/m2 27.5 (24.8–30.8) 27.4 (24.8–30.5) 27.5 (24.9–30.8) 27.5 (24.9–30.5) 27.5 (24.7–30.6) 27.3 (24.6–30.5)
 GRACE risk score nomogram 130 (112–150) 130 (112–149) 128 (110–145) 127 (110–145) 133 (114–154) 134 (116–153)
Cardiovascular risk factors, n (%)
 Current smoking 1636 (29.4) 1640 (29.9) 1000 (34.8) 960 (33.8) 636 (23.6) 680 (25.6)
 Hypertension 3915 (70.2) 3835 (69.8) 1881 (65.5) 1886 (66.4) 2034 (75.3) 1949 (73.4)
 Dyslipidaemia 2885 (51.8) 2852 (51.9) 1515 (52.8) 1569 (55.2) 1370 (50.7) 1283 (48.3)
 Diabetes mellitus 1608 (28.9) 1520 (27.7) 756 (26.3) 747 (26.3) 852 (31.6) 773 (29.1)
Medical history, n (%)
 Angina pectoris 2932 (52.6) 2890 (52.6) 1337 (46.5) 1356 (47.7) 1595 (59.1) 1534 (57.8)
 Myocardial infarction 1400 (25.1) 1410 (25.7) 609 (21.2) 608 (21.4) 791 (29.3) 802 (30.2)
 Congestive heart failure 397 (7.1) 429 (7.8) 99 (3.4) 103 (3.6) 298 (11.0) 326 (12.3)
 Percutaneous coronary intervention (PCI) 944 (16.9) 918 (16.7) 537 (18.7) 517 (18.2) 407 (15.1) 401 (15.1)
 Coronary artery bypass graft (CABG) 434 (7.8) 474 (8.6) 214 (7.4) 218 (7.7) 220 (8.1) 256 (9.6)
 Transient ischaemic attack 185 (3.3) 189 (3.4) 82 (2.9) 74 (2.6) 103 (3.8) 115 (4.3)
 Non-hemorrhagic stroke 246 (4.4) 243 (4.4) 81 (2.8) 98 (3.5) 165 (6.1) 145 (5.5)
 Peripheral arterial disease 400 (7.2) 413 (7.5) 174 (6.1) 204 (7.2) 226 (8.4) 209 (7.9)
 Chronic renal disease 273 (4.9) 279 (5.1) 117 (4.1) 108 (3.8) 156 (5.8) 171 (6.4)
Physical findings, median (25th–75th percentile)
 Heart rate (bpm) 72 (64–80) 72 (64–81) 71 (62–80) 72 (63–80) 72 (64–82) 72 (64–82)
 Systolic blood pressure (mmHg) 135 (120–150) 134 (120–150) 135 (120–150) 135 (120–150) 134 (120–150) 132 (120–150)
 Diastolic blood pressure (mmHg) 80 (70–89) 80 (70–87) 80 (70–89) 80 (70–87) 80 (70–89) 80 (70–87)
Risk indicators, n (%)
 Troponin positive, n (%) 4356 (80.8) 4323 (81.3) 2522 (89.6) 2486 (89.3) 1834 (71.3) 1837 (72.4)
 ST depression (≥1 mm) 3158 (56.8) 3201 (58.4) 1547 (54.0) 1535 (54.2) 1611 (59.8) 1666 (62.8)
 TIMI risk score > 2 4838 (89.7) 4785 (89.8) 2584 (91.3) 2566 (91.8) 2254 (88.0) 2219 (87.7)
Type of ACS at discharge, n (%)
 STEMI 449 (8.1) 437 (8.0) 330 (11.5) 305 (10.7) 119 (4.4) 132 (5.0)
 NSTEMI 3605 (64.8) 3525 (64.3) 2045 (71.2) 2025 (71.3) 1560 (58.0) 1500 (56.7)
 UA/other 1509 (27.1) 1524 (27.8) 497 (17.3) 510 (18.0) 1012 (37.6) 1014 (38.3)
Antithrombotic treatment during index hospitalization, n (%)
 Aspirin 5386 (96.6) 5316 (96.8) 2797 (97.4) 2779 (97.8) 2589 (95.9) 2537 (95.8)
 Unfractionated heparin 2910 (52.1) 2856 (51.9) 1845 (64.2) 1845 (64.9) 1065 (39.3) 1011 (38.0)
 Low molecular weight heparin 3181 (57.0) 3084 (56.1) 1568 (54.6) 1501 (52.8) 1613 (59.6) 1583 (59.6)
 Fondaparinux 194 (3.5) 191 (3.5) 87 (3.0) 76 (2.7) 107 (4.0) 115 (4.3)
 Bivalirudin 140 (2.5) 133 (2.4) 135 (4.7) 122 (4.3) 5 (0.2) 11 (0.4)
 GP IIb/IIIa inhibitor 1170 (21.0) 1117 (20.3) 982 (34.2) 963 (33.9) 188 (6.9) 154 (5.8)
Other drug from randomization to end of study, n (%)
 Beta-blocker 4768 (85.4) 4685 (85.2) 2536 (88.3) 2512 (88.4) 2232 (82.4) 2173 (81.8)
 ACE-inhibitor and/or ARB 4693 (84.2) 4602 (83.8) 2447 (85.2) 2433 (85.6) 2246 (83.2) 2169 (81.9)
 Statin 5196 (93.1) 5109 (92.9) 2777 (96.7) 2745 (96.6) 2419 (89.3) 2364 (88.9)
 Proton-pump inhibitor 2776 (49.7) 2613 (47.5) 1618 (56.3) 1536 (54.1) 1158 (42.8) 1077 (40.5)
 Calcium channel inhibitor 1553 (27.8) 1515 (27.6) 720 (25.1) 723 (25.4) 833 (30.8) 792 (29.8)
 Diuretic 2393 (42.9) 2280 (41.5) 1073 (37.3) 1037 (36.5) 1320 (48.9) 1243 (46.9)
Invasive procedures
 Coronary angiography
  During first 10 days, n (%) 4143 (74.5) 4072 (74.2) 2873 (100.0) 2841 (100.0) 1270 (47.2) 1231 (46.6)
  After first 10 days, n (%) 357 (6.4) 335 (6.1) 0 (0) 0 (0) 357 (13.3) 335 (12.7)
PCI
  During first 10 days, n (%) 2590 (46.4) 2550 (46.4) 2590 (90.1) 2550 (89.8) 0 (0) 0 (0)
  After first 10 days, n (%) 279 (5.0) 291 (5.3) 11 (0.4) 3 (0.1) 268 (9.9) 288 (10.8)
CABG
  During first 10 days, n (%) 296 (5.3) 305 (5.5) 296 (10.3) 305 (10.7) 0 (0) 0 (0)
  After first 10 days, n (%) 382 (6.8) 375 (6.8) 55 (1.9) 55 (1.9) 327 (12.1) 320 (12.0)